--- title: "Pre-Market Trend | Elevance Health (ELV.US): Golden Cross Confirms the Rebound, Volume Is the Test" type: "News" locale: "en" url: "https://longbridge.com/en/news/297792836.md" description: "Elevance Health (ELV.US) printed a daily MACD golden cross above the zero line yesterday, confirming that bullish momentum is rebuilding after a three-session pullback. The stock ended the streak by closing higher against a falling market, reclaiming its 20-day moving average on turnover of about USD 444 million. Company news adds support: its health-services unit Carelon said on September 1 it will cover Guardant Health's Shield colorectal cancer blood screening test from November 15, extending coverage to roughly 90 million Americans, about 75% of eligible adults aged 45 and older. TD Cowen raised its price target to USD 465 on July 14 while keeping a Buy rating, and second-quarter 13F filings released in late August showed Mitsubishi UFJ Asset Management, Jefferies and others establishing new or larger positions. Technically, the stock sits back above its 5-, 10- and 20-day moving averages, though turnover remains below the year's more active stretches. The near-term bias is constructive. Sustainability comes down to whether volume keeps expanding as the rally extends and whether the broad market steadies under rate and geopolitical pressure." datetime: "2026-09-02T13:18:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297792836.md) - [en](https://longbridge.com/en/news/297792836.md) - [zh-HK](https://longbridge.com/zh-HK/news/297792836.md) generator: "portal-rs" --- # Pre-Market Trend | Elevance Health (ELV.US): Golden Cross Confirms the Rebound, Volume Is the Test Elevance Health (ELV.US) printed a daily MACD golden cross above the zero line yesterday, a fresh signal that the stock is stabilizing after a three-session pullback. The gain snapped that losing streak and put the stock back above its 20-day moving average. It came despite a weak tape, with the three major US indices falling as US-Iran tensions lifted oil and Treasury yields climbed on rate-hike worries. The backdrop makes the move look stock-specific rather than market-driven. Turnover of about USD 444 million was a clear step up from the shrinking volumes of late last week, improving the volume-price mix behind the bounce. Carelon, Elevance's health-services unit, announced on September 1 that it will provide insurance coverage for Guardant Health's Shield, a blood-based colorectal cancer screening test, starting November 15. Coverage will extend to roughly 90 million people, about 75% of eligible Americans aged 45 and older, and the market read the move as Carelon pushing deeper into preventive screening and value-based care. Analysts are constructive as well: TD Cowen raised its price target on Elevance to USD 465 on July 14 while keeping a Buy rating. Second-quarter 13F filings, disclosed in late August, showed Mitsubishi UFJ Asset Management, Jefferies and others establishing new or larger positions in the stock. An August 22 market report said the company's second-quarter 2026 results and full-year guidance underpin the valuation. Health insurer peers firmed alongside Elevance: UnitedHealth, Cigna and Humana all rose, a sign the sector's defensive appeal was drawing buyers in a risk-off tape. The technical picture has improved, but the follow-through is still unproven. The stock sits above its 5-, 10- and 20-day moving averages again, and the short-term averages have tilted up after converging tightly. Both MACD lines are above zero, and the key test of the cross is whether the histogram keeps expanding from here. Yesterday's close also pushed the stock back toward the upper Bollinger Band, a sign of near-term strength. Turnover had dried up in the latter half of last week, then the past two sessions carried it back above USD 400 million as buyers returned. Activity still runs below the year's more active stretches, so whether the bounce has legs depends on volume staying healthy. Directionally, the near-term read stays constructive: the MACD cross, the return of buyers and supportive analyst views all point the same way. The caveats are real, though. Managed-care stocks still carry worries over medical costs and policy uncertainty, and Elevance trades about 8% below its 52-week high, so this bounce reads as an oversold recovery more than a fresh trend. What to watch: whether the stock holds the 20-day moving average, whether the health care sector ETF (XLV.US) sustains its relative strength, and whether the broad market steadies under rate and geopolitical pressure. If the market rolls over on rate-hike expectations or geopolitical stress, or if volume fades, the bounce could give way to range-bound trade. Volume-price fit and sector leadership are the two readings that will settle the question. *This content is for informational purposes only and does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security or capital markets product. It has been prepared without regard to your individual investment objectives, financial situation, or particular needs. Investing involves risk, including the possible loss of principal; past performance is not indicative of future results. Longbridge and its affiliates accept no liability for any loss arising from reliance on this material.* ### Related Stocks - [ELV.US](https://longbridge.com/en/quote/ELV.US.md) ## Related News & Research - [Elevance Health CEO Gail Boudreaux acquires common shares worth $1,003,428.45](https://longbridge.com/en/news/293064111.md) - [Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening | GH Stock News](https://longbridge.com/en/news/297650116.md) - [Vista Investment Management Makes New $2.14 Million Investment in Elevance Health, Inc. $ELV](https://longbridge.com/en/news/296699815.md) - [TrinityBridge Ltd Acquires New Position in Elevance Health, Inc. $ELV](https://longbridge.com/en/news/296605778.md) - [Csenge Advisory Group Makes New Investment in Elevance Health, Inc. $ELV](https://longbridge.com/en/news/296457970.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**